Soheil Meshinchi, MD, Pediatric Hematology & Oncology, Seattle, WA, Seattle Children's Hospital

SoheilMeshinchiMDPhD

Pediatric Hematology & Oncology Seattle, WA

Cancer Genetics/Cancer Risk Assessment

- Member, Fred Hutchinson Cancer Research Center - Professor of Pediatrics, University of Washington School of Medicine

Dr. Meshinchi is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Meshinchi's full profile

Already have an account?

Education & Training

  • Fred Hutchinson Cancer Res CenterFellowship, Pediatric Hematology/Oncology, 1997 - 2000
  • University of Washington
    University of WashingtonFellowship, Pediatric Hematology/Oncology, 1997 - 2000
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pediatrics, 1994 - 1997
  • Wayne State University School of Medicine
    Wayne State University School of MedicineClass of 1994
  • University of MichiganPh.D., Pharmacology, 1985 - 1990
  • The University of Michigan School of MedicinePh.D., 1985 - 1990
  • The University of MichiganB.S., Microbiology, 1980 - 1984

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1998 - 2022

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Acute Myeloid Leukemia in Children and Adolescents: Identification of New Molecular Targets Brings Promise of New Therapies  
    Soheil Meshinchi, MD, Hematology ASH Education Program
  • Prognostic Impact of T(16;21)(p11;q22) and T(16;21)(q24;q22) in Pediatric AML: A Retrospective Study by the I-BFM Study Group  
    Soheil Meshinchi, Tanja A Gruber, Blood
  • Pan-cancer Genome and Transcriptome Analyses of 1,699 Pediatric Leukemias and Solid Tumors  
    Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pou..., Nature Medicine, 1/1/2018
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies
    Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene _ a COG/Tpaml Study
    Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous...
    Soheil Meshinchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and More
    Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019
  • The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in Funding
    The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in FundingNovember 8th, 2018
  • Study Finds Differences Between Adult and Childhood Leukemia, Calls for Developing Age-Specific Cancer Treatments
    Study Finds Differences Between Adult and Childhood Leukemia, Calls for Developing Age-Specific Cancer TreatmentsDecember 11th, 2017
  • Join now to see all

Hospital Affiliations